Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.74 |
| ▸ | PNP | P00491 | 11/20 | 0.70 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536007 | 1.00 | TK1 (0.74) | TK1PNPHPRT1KMT2A | |
| SCHEMBL22571178 | 1.00 | TK1 (0.74) | TK1PNPHPRT1KMT2A | |
| SCHEMBL6272299 | 1.00 | TK1 (0.74) | TK1PNPHPRT1KMT2A | |
| Hydrochloric Acid SCHEMBL258897 | 0.99 | TK1 (0.73) | TK1PNPHPRT1KMT2A | |
| SCHEMBL8522271 | 0.99 | TK1 (0.76) | TK1PNPHPRT1KMT2A | |
| SCHEMBL6272731 | 0.95 | TK1 (0.74) | TK1PNPHPRT1 | |
| Phosphonic Acid SCHEMBL28142169 | 0.94 | TK1 (0.70) | TK1PNPHPRT1 | |
| SCHEMBL667796 | 0.89 | TK1 (0.69) | TK1PNPHPRT1 | |
| SCHEMBL16056722 | 0.87 | TK1 (0.74) | TK1PNPHPRT1 | |
| SCHEMBL8175624 | 0.87 | TK1 (0.97) | TK1PNPHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101460178-B | Immune regulative RNA (SIMRA) compound for the stabilisation of TLR7 and TLR8 | 艾德拉药物股份有限公司 | 2016-12-07 | — | — | CN | claimed |
| US-20160089393-A1 | COMPOSITION AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA | BLUEBERRY THERAPEUTICS LIMITED (GB) | 2016-03-31 | — | — | US | claimed |
| EP-2986285-A1 | COMPOSITIONS AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA | Blueberry Therapeutics Limited (GB) | 2016-02-24 | — | — | EP | claimed |
| US-9243050-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | Idera Pharamaceuticals, Inc. (US) | 2016-01-26 | — | — | US | claimed |
| EP-2021008-B1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS INC (US) | 2015-12-02 | — | — | EP | claimed |
| EP-1934239-B1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS INC (US) | 2015-07-15 | — | — | EP | claimed |
| WO-2014170683-A1 | COMPOSITIONS AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA | BLUEBERRY THERAPEUTICS LIMITED (GB) | 2014-10-23 | — | — | WO | claimed |
| US-20140308300-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2014-10-16 | — | — | US | claimed |
| US-8853375-B2 | Toll like receptor modulators | IDERA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-8759310-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-20130202584-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS, INC. | 2013-08-08 | — | — | US | claimed |
| US-8106173-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | claimed |
| JP-2009533348-A | — | — | 2009-09-17 | — | — | JP | claimed |
| CN-101460178-A | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS INC (US) | 2009-06-17 | — | — | CN | claimed |
| EP-2021008-A2 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | Idera Pharmaceuticals, Inc. (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | IDERA PHARMACEUTICALS, INC. | 2008-07-17 | — | — | US | claimed |
| WO-2007117686-A2 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-12279614-B2 | Photo-polymerizable, universal antimicrobial coating to produce high-performing, multi-functional face masks | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2025-04-22 | — | — | US | disclosed |
| US-20050004144-A1 | Combined use of IMPDH inhibitors with toll-like receptor agonists | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-01-06 | — | — | US | disclosed |
| JP-2001055528-A | RECEPTIVE INK AND PRINTING SUBSTRATE AND PRINTING ARTICLE USING SAME | TEIKOKU PRINTING INKS MFG CO LTD | 2001-02-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12279614-B2 | Photo-polymerizable, universal antimicrobial coating to produce high-performing, multi-functional face masks | CUTA, PUF60, PARN | TK1 4797/4885PNP 3750/4885HPRT1 3628/4885 |
| US-20050004144-A1 | Combined use of IMPDH inhibitors with toll-like receptor agonists | IMPDH1, TLR3, IMPDH2 | TK1 370/4885PNP 55/4885HPRT1 73/4885 |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | TLR8, TLR7, TLR9 | TK1 353/4885PNP 46/4885HPRT1 596/4885 |
| US-20130202584-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | TLR8, TLR7, TLR9 | TK1 2040/4885PNP 406/4885HPRT1 913/4885 |
| US-20140308300-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | TLR8, TLR7, TLR9 | TK1 2040/4885PNP 406/4885HPRT1 913/4885 |
| US-20160089393-A1 | COMPOSITION AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA | BPGM, PGM2, PMM2 | TK1 2721/4885PNP 1363/4885HPRT1 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.